Business Context and Reporting Period
This Form 8-K filing by ChromaDex Corporation (CDXC) reports on events occurring on January 3, 2023. The filing focuses on corporate governance and executive compensation rather than operational or financial performance results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding personnel changes and does not contain financial statements.
Material Changes
The primary material change reported is the appointment of Brianna Gerber as Chief Financial Officer, effective January 1, 2023. Ms. Gerber previously served as SVP, Finance / Interim Chief Financial Officer since August 11, 2022.
Management Commentary and Compensation Details
In connection with the appointment, the Company entered into an employment agreement with Ms. Gerber containing the following terms:
- Base Salary: $325,000 annually.
- Annual Bonus: Discretionary target of 50% of base salary based on performance goals.
- Long-Term Incentives: Target annual opportunity of 70% of base salary (adjusted by Black Scholes calculation).
- Termination Benefits (Without Cause/Good Reason):
- 12 months' base salary continuation.
- Pro-rata bonus for the year of termination.
- COBRA health insurance premium payments for 12 months.
- Accelerated vesting of equity awards (12-month acceleration generally; full acceleration if within 18 months of a corporate transaction).
- Extended exercise period for options/SARs (additional 2 years post-termination).
The agreement requires the execution of a release of claims to receive termination benefits (except in cases of death). An indemnification agreement was also executed on standard terms.
Investor Verification Checklist
- Verify the effective date of the CFO appointment (January 1, 2023) against the press release dated January 5, 2023.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "corporate transaction."
- Confirm the impact of the new CFO appointment on the company's financial reporting timeline and internal controls.
- Check subsequent filings for any changes to the compensation structure or equity grant details.